Want to see SE:SCIB full AI Analyst Report?
SCIB Stock Chart & Stats
kr0.33
>-kr0.01(-1.65%)
At close: 4:00 PM EST
kr0.33
>-kr0.01(-1.65%)
Day’s Range― - ―
52-Week Rangekr15.45 - kr51.34
Previous CloseN/A
Volume1.41K
Average Volume (3M)4.49K
Market Cap
kr222.14M
Enterprise Valuekr318.37
Total Cash (Recent Filing)kr37.15M
Total Debt (Recent Filing)kr23.21M
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.91
Shares Outstanding14,059,788
10 Day Avg. Volume3,525
30 Day Avg. Volume4,492
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.92
Revenue Forecast (FY)kr65.90M
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthThe acceleration in revenue growth indicates improving commercial traction after a weak 2025. If sustained, a larger installed base and higher clinical usage could help SciBase spread fixed costs, support operating leverage, and strengthen the platform’s longer-term path toward scale.
Solid Gross MarginA gross margin near 59% provides meaningful contribution from each unit of revenue before operating expenses. This supports the economics of continued Nevisense adoption and gives management a foundation to improve profitability as revenue scales, provided operating costs become more disciplined.
Recurring Usage ModelThe combination of upfront system placements with usage-driven consumables and service revenue can create repeat economics beyond the initial device sale. A growing clinical customer base may therefore produce more predictable revenue and deepen customer engagement over multiple testing cycles.
Bears Say
Persistent Deep LossesThe scale of current losses shows that revenue and gross profit are not yet sufficient to support the operating cost base. Continued losses can delay self-funded expansion, limit strategic flexibility, and make future profitability dependent on substantial revenue growth or cost reduction.
Heavy Cash BurnMaterially negative operating and free cash flow means the business is consuming cash while it develops commercial scale. Unless cash generation improves meaningfully, SciBase may remain reliant on external funding, reducing its ability to invest and increasing financial pressure over the next several quarters.
Funding Risk From Balance-Sheet VolatilityAlthough current leverage is moderate, the sharp prior change demonstrates that the balance sheet can deteriorate materially during periods of loss. Further losses could weaken equity again, increase dependence on financing, and raise dilution or funding risk despite the improved TTM position.
SciBase Holding AB News
SCIB FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was kr15.45 and its highest was kr51.34 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is kr222.14M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is Nov 12, 2026 which is in 56 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on Aug 19, 2026. The company reported -kr2.691 earnings per share for the quarter.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 14,059,788 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -kr2.691 in its last earnings report. Following the earnings report the stock price went down -11.362%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in SE:SCIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.